Pharmaceuticals

Quit Smoking Drugs Market Future Outlook: Strong Growth Expected Toward $90.73 Billion by 2030

February 24, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the quit smoking drugs market from 2026–2035 with trusted insights from The Business Research Company

What is the expected shift in the Quit Smoking Drugs Market’s size between 2026 and 2030?

The quit smoking drugs market has demonstrated rapid growth in its size over recent years. It is forecast to expand from $44.23 billion in 2025 to reach $50.94 billion in 2026, achieving a compound annual growth rate (CAGR) of 15.2%. The contributing factors to this historical growth include increasing awareness of smoking hazards, a rising prevalence of smoking-related diseases, the availability of nicotine replacement therapies, government anti-smoking campaigns, and the growth of pharmaceutical manufacturing in emerging markets.

The quit smoking drugs market size is anticipated to undergo significant expansion in the upcoming years, projected to reach $90.73 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 15.5%. This growth during the forecast period is attributed to advancements in digital health solutions, the increasing adoption of personalized medicine, the integration of artificial intelligence in treatment monitoring, the expansion of telemedicine services, and the rise of wearable health monitoring devices. Noteworthy trends for this period encompass personalized nicotine replacement therapies, mobile health (mhealth) and smoking cessation applications, telemedicine-supported prescription services, the incorporation of behavioral therapy with drug treatments, and wearable devices for monitoring cravings.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=9247&type=smp

Which Drivers Are Shaping Strategic Decisions In The Quit Smoking Drugs Market?

The increasing prevalence of smoking addiction is projected to fuel the expansion of the quit-smoking drug market. Smoking involves the act of inhaling and exhaling vapors from burning plant materials, such as tobacco, marijuana, or hashish, among others. Quit smoking drugs are designed to diminish the desire to smoke by interfering with an individual’s tobacco cravings. These prescription medications are utilized to manage nicotine withdrawal symptoms, thereby effectively supporting individuals in their efforts to stop smoking. For example, data from November 2025 by the OECD, a France-based intergovernmental international organization, revealed that in 2023, 14.8% of individuals aged 15 and over engaged in daily smoking. The highest rates of daily smokers were observed in Türkiye, Hungary, and Greece, alongside accession/partner countries like Indonesia, Bulgaria, and China, where a minimum of one in four people smoked daily. On average, daily smoking affected 18.5% of men in 2023, compared to 11.4% of women. Consequently, the rising incidence of smoking addiction is a key factor driving the growth of the quit-smoking drug market.

What Segment Classifications Make Up The Quit Smoking Drugs Market?

The quit smoking drugs market covered in this report is segmented –

1) By Product: Drug Therapy, E-Cigarettes, Nicotine Inhalers, Nicotine Replacement Therapies, Nicotine Sublingual Tablets

2) By Drug: Varenicline (Chantix), Bupropion (Zyban), Other Drugs

3) By Distribution: Drug Store, Online Pharmacies, Retail Pharmacies

Subsegments:

1) By Drug Therapy: Bupropion (Zyban), Varenicline (Chantix)

2) By E-Cigarettes: Disposable E-Cigarettes, Rechargeable E-Cigarettes, Pod Systems

3) By Nicotine Inhalers: Prescription Inhalers, Over-The-Counter Inhalers

4) By Nicotine Replacement Therapies (NRT): Nicotine Patches, Nicotine Gum, Nicotine Lozenges

5) By Nicotine Sublingual Tablets: Fast-Acting Sublingual Tablets, Extended-Release Sublingual Tablets

Which Trends Are Influencing The Performance And Direction Of The Quit Smoking Drugs Market?

Leading companies in the quit smoking drugs market are concentrating on developing new formulations and delivery methods, such as generic tablets, to expand their market leadership across various regions and gain a competitive edge. Generic varenicline tablets are unbranded versions of the medication containing varenicline tartrate, which are bioequivalent to the original branded product and utilized for smoking cessation therapy. For instance, in January 2024, Lupin Limited, an India-based pharmaceutical company, launched new Varenicline tablets in the United States, available in 0.5 mg and 1 mg strengths. These tablets are the generic equivalents of Chantix tablets (0.5 mg and 1 mg) from PF Prism C.V. and are employed to assist in smoking cessation treatment. As a partial agonist of the nicotinic acetylcholine receptor, varenicline functions by stimulating the release of dopamine, which can alleviate withdrawal symptoms and cravings associated with nicotine addiction. This dual mechanism allows it to reduce the pleasurable effects of smoking while concurrently providing some stimulation to minimize withdrawal effects.

Which Key Market Players Are Investing In Expansion And Innovation Within The Quit Smoking Drugs Market?

Major companies operating in the quit smoking drugs market are 22nd Century Group, Cipla Limited, Dr. Reddy’s Laboratories, GSK Plc., Johnson & Johnson, NJOY LLC, Perrigo Company Plc, Pfizer Inc., Philip Morris International, Glenmark Pharmaceuticals Limited, Zydus Cadila Healthcare Limited, BioCorRx Inc., Ennaid Therapeutics LLC, Fertin Pharma A/S, Hikma Pharmaceuticals PLC, IntelGenx Technologies Corp., Innovus Pharmaceuticals Inc., Gilla Inc., Rusan Pharma Ltd., Novartis AG

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/quit-smoking-drugs-global-market-report

Which Regions Are Poised For Strategic Growth In The Quit Smoking Drugs Market?

North America was the largest region in the quit smoking drugs market in 2025. The regions covered in the quit smoking drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Quit Smoking Drugs Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=9247&type=smp

Browse Through More Reports Similar to the Global Quit Smoking Drugs Market 2026, By The Business Research Company

Quit Smoking Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/quit-smoking-drugs-global-market-report

Nicotine Addiction Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/nicotine-addiction-treatment-global-market-report

Nicotine Addiction Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/nicotine-addiction-treatment-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795